TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03221179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7049665
Description: A single ascending dose (starting dose 1.5 micrograms \[mcg\])of RO7049665 will be administered SC.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered SC once.
Study: NCT02915250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® Combo
Description: Injection of BioChaperone® Combo
Study: NCT01357642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine inhalation aerosol
Description: Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for epinephrine inhalation aerosol, formulation without epinephrine
Study: NCT02915250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog® Mix25
Description: Injection of Humalog® Mix25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Injection of Humalog®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Injection of Lantus®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection of 0.9% NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injection of 0.9% NaCl
Study: NCT01357642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine inhalation aerosol
Description: epinephrine inhalation aerosol, 220 mcg/inhalation, 2 inhalations QID at 4-6 hour intervals
Study: NCT00292097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early tracheostomy
Description: early conversion - less than or equal to 72 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late tracheostomy
Description: Late conversion (10-14 days)
Study: NCT02595372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study: NCT04600986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated dose of GnRH agonist
Description: 0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.

Intervention type: OTHER
Group type: OTHER
Intervention: Repeated dose of GnRH agonist
Description: 0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.
Study: NCT00561106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone- valacyclovir
Description: prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone-placebo
Description: prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
Study: NCT02464605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SEL-037 (pegsiticase)
Description: Intravenous infusion of SEL-037
Study: NCT03242902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy intensity 1
Description: Exposure to white light (10.000 lux) in the morning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy intensity 2
Description: Exposure to white light (10-20 lux) in the morning
Study: NCT02688530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Dexamethasone 4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Dexamethasone 6mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Dexamethasone 8mg
Study: NCT02337621

Intervention type: OTHER
Intervention: No intervention
Study: NCT01540942

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutrition treat
Description: intestinal nutrition treat :female：REE（Kcal/d）=655+9.6W+1.7H-4.7A; male：REE（Kcal/d）=66+13.7W+5.0H-6.8A;\[W=weight（Kg）；H=height（cm）；A=age（year）\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: bowel resection
Study: NCT02977767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conversational hypnosis
Description: Conversational hypnosis starts since the enter of the nurse in patient's room and last since the nurse leaves the room. Change of canula is performed under conversational hypnosis.
Study: NCT01769378

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ
Study: NCT01108237

Intervention type: OTHER
Group type: OTHER
Intervention: TruMatch™ Personalized Solutions
Description: TruMatch™ Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon.

Intervention type: DEVICE
Group type: OTHER
Intervention: Total Knee Arthroplasty with Conventional Instrumentation.
Description: Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments, not TruMatch™ instrumentation.
Study: NCT00039481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00777335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat - LBH589
Description: Solution for infusion - 25mg/5ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat - LBH589
Description: Hard gelatine capsules - 5mg and 20 mg
Study: NCT03570268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group: Education
Description: Participants in the experimental intervention group received an educational program and tailored home exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Usual care
Description: Participants allocated to the control group received stretching exercises.
Study: NCT04654559

Intervention type: OTHER
Group type: OTHER
Intervention: Unobtrusive data collection using wearable non-invasive sensors
Description: Two wearable non-invasive sensors will be mounted to the patients skin (lateral rib cage and foot). These wearable non-invasive sensors are measuring unobtrusively skin based parameters (no diagnosis will be made), which will be used for fever detection algorithm development..
Study: NCT03285555

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STRATIFIX
Description: STRATIFIX symmetric PDS Plus; Stratifix knotless suture

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VICRYL
Description: Vicryl #1
Study: NCT01769378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Administered PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Administered PO
Study: NCT02896088

Intervention type: OTHER
Group type: OTHER
Intervention: decayed tooth surfaces
Description: The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.

Intervention type: OTHER
Group type: OTHER
Intervention: decayed tooth surfaces
Description: The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.
Study: NCT01521442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Yoga Therapy
Description: Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list Control
Description: Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
Study: NCT03232203

Intervention type: DRUG
Intervention: STRIMVELIS
Description: It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study

Intervention type: DRUG
Intervention: STRIMVELIS
Description: It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study
Study: NCT01989520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase IIb formulation
Description: Single oral dose 45mg AZD5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Putative phase III formulation
Description: Single oral dose 45mg AZD5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow dissolution variant 1
Description: Single oral dose 45mg AZD5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow dissolution variant 2
Description: Single oral dose 45mg AZD 5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test treatment E
Description: Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
Study: NCT01665170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Passiflora incarnata
Description: 3 x 1 tablet per day for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 1 ablet per day for 3 days
Study: NCT04040920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone
Description: One minute of pretreatment with ozone by using the OzoneDTA device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pits and fissure sealants
Description: cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pits and fissure sealants
Description: cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';
Study: NCT02863302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology treatment
Description: All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment.
Study: NCT03123822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses
Description: Glasses traditionally prescribed for refractive error

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses
Description: Glasses traditionally prescribed for refractive error

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses
Description: Glasses traditionally prescribed for refractive error
Study: NCT05011344

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Seroneutralization and Elisa tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Seroneutralization and Elisa tests
Study: NCT02357264

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound of the chest for the detection of fluid in the lung

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound of the chest for the detection of fluid in the lung
Study: NCT03503305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adipose-derived stem cell injection
Description: 5 ml injection of adipose derived stem cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: 5 ml injection of corticosteroid
Study: NCT01945476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam premedication
Description: On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.~Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam premedication
Description: On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.~Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total.
Study: NCT01302210

Intervention type: DRUG
Intervention: Decolonization
Description: 5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
Study: NCT02145637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib plus Ruxolitinib combination therapy
Study: NCT00462449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) through the Ness H200
Description: Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
Study: NCT03078309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis
Description: single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis
Description: single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)
Study: NCT03116724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: central venous catheterization through Rt. IJV
Description: * insertion at the intersection of the cricoid cartilage level and the triangular point where the sternal head of the SCM muscle meets the clavicular head~* placement of the tip of the catheter 2 cm away from the junction between right atrium and superior vena cava using TEE~* measurement of the depth of the catheter at insertion point
Study: NCT03637790

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.

Intervention type: OTHER
Group type: OTHER
Intervention: rifampin
Description: In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842
Study: NCT00980733

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified Yoghurt
Description: The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yoghurt
Description: Plain yoghurt same as in intervention group without fortification
Study: NCT00815503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Approved by the Danish Medicines Agency

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT02644447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HUC-MSCs Transplantation
Description: The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HUC-MSCs with Injectable Collagen Scaffold Transplantation
Description: The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
Study: NCT03042910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib 1 mg orally once daily.
Study: NCT01496417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
Study: NCT02725437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Vaccine
Description: 0.5 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Vaccine
Description: 0.5 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Vaccine
Description: 0.5 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Vaccine
Description: 0.5 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL intramuscular injection
Study: NCT03010241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangbi (prescription)
Description: A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Study: NCT03083808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV every 21 days~+~Physician's choice chemotherapy with one of the following every 21 days:~* Docetaxel 75mg/m2 IV~* Pemetrexed 500mg/m2 IV (non-squamous only)~* Gemcitabine 1000mg/m2 IV on days 1 and 8
Study: NCT03711136

Intervention type: PROCEDURE
Intervention: aortic prosthesis
Description: ascending aortic and/or aortic arch prosthesis with linear vascular prosthesis or hybrid prosthesis

Intervention type: PROCEDURE
Intervention: aortic prosthesis
Description: ascending aortic and/or aortic arch prosthesis with linear vascular prosthesis or hybrid prosthesis
Study: NCT01138527

Intervention type: OTHER
Intervention: MRI examination
Description: 45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging